142 related articles for article (PubMed ID: 23932362)
21. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Martin SE; Sausen M; Joseph A; Kingham BF
Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399
[No Abstract] [Full Text] [Related]
22. Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
Yamaguchi M; Munemoto S; Kasada A; Murata R; Ueda M
Leuk Res; 2010 Sep; 34(9):e237-9. PubMed ID: 20371117
[No Abstract] [Full Text] [Related]
23. Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Olsson-Strömberg U; Hermansson M; Lundán T; Ohm AC; Engdahl I; Höglund M; Simonsson B; Porkka K; Barbany G
Eur J Haematol; 2010 Nov; 85(5):399-404. PubMed ID: 20659155
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J
Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627
[TBL] [Abstract][Full Text] [Related]
25. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
Kroll T; Ames MB; Pruett JA; Fenske TS
Leuk Lymphoma; 2010 Sep; 51(9):1751-3. PubMed ID: 20629520
[No Abstract] [Full Text] [Related]
26. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
28. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS
ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252
[TBL] [Abstract][Full Text] [Related]
29. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
30. Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Tiribelli M; Latagliata R; Luciano L; Castagnetti F; Gozzini A; Cambrin GR; Annunziata M; Stagno F; Pregno P; Albano F; Abruzzese E; Musto P; Montefusco E; Fava C; Fanin R; Pane F; Rosti G; Breccia M; Alimena G; Vigneri P
Ann Hematol; 2013 Jan; 92(2):179-83. PubMed ID: 23053188
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib.
Lindauer M; Hochhaus A
Recent Results Cancer Res; 2014; 201():27-65. PubMed ID: 24756784
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation.
Nakata J; Okada M; Tamaki H; Satake A; Kaida K; Yoshihara S; Kato R; Ikegame K; Ogawa H
Leuk Res; 2011 Dec; 35(12):1658-9. PubMed ID: 21794916
[No Abstract] [Full Text] [Related]
34. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Bagadi S; Saikia T; Pany A; Das B
Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
[TBL] [Abstract][Full Text] [Related]
35. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
[TBL] [Abstract][Full Text] [Related]
36. [New horizon of chronic myelogenous leukemia].
Tauchi T; Ohyashiki K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():617-21. PubMed ID: 17474470
[No Abstract] [Full Text] [Related]
37. Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
Chen Y
Leuk Res; 2011 Jan; 35(1):27-9. PubMed ID: 20723974
[No Abstract] [Full Text] [Related]
38. Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.
Raanani P
Acta Haematol; 2013; 130(2):108-10. PubMed ID: 23548690
[No Abstract] [Full Text] [Related]
39. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
Abdelhalim A; Barcos M; Block AW; Sait SN; Starostik P; Wetzler M; Wang ES
Leuk Lymphoma; 2007 May; 48(5):1053-6. PubMed ID: 17487757
[No Abstract] [Full Text] [Related]
40. Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
Kobayashi-Watanabe N; Sato A; Watanabe T; Abe T; Nakashima C; Sueoka E; Kimura S; Sueoka-Aragane N
Lung Cancer; 2017 Aug; 110():35-41. PubMed ID: 28676216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
